Paul Knight Analyst Performance

Paul Knight is a Managing Director and Equity Research Analyst for KeyBanc Capital Markets Inc. His research coverage focuses on Healthcare, specifically the Life Science Technology, Bioproduction, and Diagnostics sectors. Prior to joining KeyBanc Capital Markets in fall 2020, Knight spent seven years as an Equity Research Analyst covering Life Science Technology at Janney, Montgomery & Scott in New York. Before that, he covered Life Science Technology for Credit Agricole Securities (CLSA) for three years. His previous professional experience includes being a founding partner and analyst at Thomas Weisel Partners Group (Stifel Financial), a senior analyst at Salomon Brothers, as well as a political analyst for NatWest Securities in New York and Washington, D.C., covering Food and Drug Administration and congressional committee meetings. Knight earned an MBA in finance from George Washington University in Washington, D.C., and a Bachelor of Science in economics from the University of Nebraska. He is a Chartered Financial Analyst, and also holds the Series 7, 62, 86, and 87 industry licenses. Knight has been ranked as a top research analyst multiple times by surveys including Institutional Investor, Greenwich Associates, and The Wall Street Journal. He has delivered keynote addresses for several significant industry events, such as the Analytical & Life Sciences and Industry Association CEO Roundtable and the American Chemical Society’s annual meeting.